A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis

Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehrlich, Dean, Jamaluddin, Nimah, Pisegna, Joseph, Padua, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832071/
https://www.ncbi.nlm.nih.gov/pubmed/29666723
http://dx.doi.org/10.1155/2018/9679287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832071/
https://www.ncbi.nlm.nih.gov/pubmed/29666723
http://dx.doi.org/10.1155/2018/9679287

Ejemplares similares